Comparative Study of Hematological Disorders of Antiviral Treatments in Algerian Chronic Hepatitis C Patients
Journal of Health and Environmental Research
Volume 5, Issue 1, March 2019, Pages: 24-31
Received: Jan. 22, 2019; Accepted: Mar. 6, 2019; Published: Mar. 21, 2019
Views 290      Downloads 33
Authors
Kamilia Guedri, Department of Biology, University Larbi Tebessi, Tebessa, Algeria
Aziez Chettoum, Department of Biology Animal, University Mentouri, Constantine, Algeria
Nawel Attoui, Department of Biology, University Tahri Mohamed, Bechar, Algeria
Article Tools
Follow on us
Abstract
Viral hepatitis C (HCV) is a major health problem that affects important number of people around the world, the emergence of new direct antiviral treatments is a real therapeutic revolution to days it allows the cure hepatitis C in the majority of patients, but these treatments is accompanied by numerous side effects. Sofosbuvir, Pegylated interferon and Ribavirin are the standard care for the treatment of chronic hepatitis C in Algeria. In this study, we are interesting to investigate hematological toxicity of Antiviral treatment in Algerian patients with chronic hepatitis C. We carried out a comparative study, which involved 300 men and women Algerian at different ages. The determination of the various Epidemiological, Hematological, biochemical (AST, ALT, Glycemia) and virological (Viral load) parameters was performed. The analysis of 300 data shows that the infection with hepatitis C affects the age group between (46 - 65 years) with a percentage of 67% with a female predominance 82% and a clear predominance of genotype 1b with a percentage (89%), Dual therapy (Sofosbuvir + Ribavirin) and triple therapy (Sofosbuvir + Ribavirin + Pegylated interferon) induce a high hematological toxicity - Hemolytic anemia ( revealed by a decrease of the number of Red blood cell and Hemoglobin level, as well as the percentage of hematocrit and the increase of mean corpuscular volume that induced the increase of red blood cell masse and the expansion) - Thrombocytopenia (revealed by the decrease in the number of platelets ) and leukopenia (translated by the decrease in the number of White blood cells and lymphocytes as well as monocytes, and a very significant increase in granulocytes) whereas in monotherapy (Sofosbuvir) a low toxicity was noticed, the Patients how receiving triple therapy (Sofosbuvir + Ribavirin + Pegylated interferon) can be developing diabetes mellitus. Antiviral treatments were significantly induced hemolytic anemia, leucopenia and thrombopenia in Algerian patients with chronic hepatitis C.
Keywords
Sofosbuvir, Ribavirin, Pegylated Interferon, Hepatitis C, Hematological Toxicity
To cite this article
Kamilia Guedri, Aziez Chettoum, Nawel Attoui, Comparative Study of Hematological Disorders of Antiviral Treatments in Algerian Chronic Hepatitis C Patients, Journal of Health and Environmental Research. Vol. 5, No. 1, 2019, pp. 24-31. doi: 10.11648/j.jher.20190501.14
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
World Health Organization Hepatitis C Factsheet; available online at:http://www.who.int/news-room/fact-sheets/detail/hepatitis-c;lastaccessed on July 1, 2018.
[2]
AASLD. Recommendations for Testing, Managing, and Treating Hepatitis C; available online at: https://www.hcvguidelines.org/; last accessed on July 1, 2018.
[3]
EASL recommendations on treatment of hepatitis C. J Hepatol; 69(2):461–511, 2018.
[4]
Manns MP, Buti M, Gane E, Pawlotsky J-M, Razavi H, Terrault N, et al. Hepatitis C virus infection. Nat Rev Dis Prim 3:17006, 2017.
[5]
Golabi P, Sayiner M, Bush H, Gerber L, Younossi Z. Patient-reported outcomes and fatigue in patients with chronic hepatitis C infection. Clin Liver Dis 21:565–578, 2017.
[6]
Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 377:1448–1455, 2017.
[7]
Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373:2618–2628, 2015.
[8]
Calleja JL, Crespo J, Rincon D, Ruiz-Antoran B, Fernandez I, Perello C, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort. J Hepatol 66:1138–1148, 2017.
[9]
Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness and predictors of sustained virological response with alloral therapy in 21, 242 hepatitis C genotype-1 patients. Antivir Ther 22:481–493, 2017.
[10]
Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol; 67:1168–1176, 2017.
[11]
Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C – the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther; 41:497–520, 2015.
[12]
Martin P, Jensen D: Ribavirin in the Treatment of Chronic Hepatitis C. J Gastroenterol Hepatol, 23:844-855, 2008.
[13]
Lashin AH, Shaheen YA, Metwally MA, El-Feky HM, Hegab MF & Abbas SM. Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin. Indian J Gastroenterol 32(5):316–323, 2013.
[14]
Pontali E, Angeli E, Cattelan AM, Maida I, Nasta P, Verucchi G, et al. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: Safety analysis of the OPERA study. Antiviral Therapy;20(1):39-48, 2015.
[15]
Wasley A & Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis.; 20(1):1-16, 2000.
[16]
Debbeche R, Said Y, Ben Temime H, El Jery K, Bouzaidi S, Salem M & Najjar T. Epidemiology of hepatitis C in Tunisia. Tunis Med; 91(2):86-90, 2013.
[17]
Hmida S, Mojaat N & Chaouchi E. HCV antibodies in hemodialyzed patients in Tunisia. Pathol Biol.;43:581-3, 1995.
[18]
Rouabhia S, Sadelaoud M, Chaabna-Mokrane K, Toumi W&Abenavoli L. Hepatitis C virus genotypes in north astern Algeria: A retrospective study. World J Hepatol; 5(7): 393–397, 2013.
[19]
Glue P. The clinical pharmacology of ribavirin. Seminars in Liver Disease. 19: 17-24, 1999. Gordien E. Virus de l’hépatite C: dynamique, réplication intracellulaire. Elsevier SAS; 13-26, 2003.
[20]
Khakoo, S., Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon L, Lypnyj D, Flannery B, Walters K & Dusheiko GM. Ribavirin and interferon alfa-2b in chronic hepatitis C:assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol; 46(6): 563-570, 1998.
[21]
Dimitrow, Y, Heibel F, Marcellin L, Chantrel F, Moulin B & Hanne D. Acute renal failure and nephrotic syndrome with alpha interferon therapy. Nephrol Dial Transplant;. 12:200-3, 1997.
[22]
Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, Keeffe EB, Rossaro L, Burnett A, Goon BL, Bowers PJ & Leitz GJ.. Erythropoietic response to anemia in chronichepatitis C patients receiving combination pegylated interferon/ribavirin.; HCV Natural History Study Group. Am J Gastroenterol; 100(2):299-307, 2005.
[23]
Kamatani N, Nakamura Y & Miyakawa Y. Influence of inosine triphosphatase gene (ITPA) polymorphism on decrease of heamoglobin during treatment with pegylated interferon, ribavirin and telaprevir. Hepatol; 40 (5): 1450-1458, 2010.
[24]
Watson J, Hassanein TI. & Kayali Z. Prospects for hepatitis C virus therapeutics: Boceprvir and telaprevir as adjuvant therapy to the standard antiviral regimen. Curr Opin Investig Drug; 4 (6): 5705-5708, 2010.
[25]
De Franceschi L, Fattovich G, Turrini F. & al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 31: 997-1004, 2000.
[26]
Krishnan SM & Dixit NM. Ribavirin-Induced Anemia in Hepatitis C Virus Patients Under going Combination Therapy. PLoSComput Biol 7(2) e1001072, 2011.
[27]
Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis. 23(2): 183-94, 2003.
[28]
Abdel Hafez H, El Beshlawy M, Mabrouk M, El-Akel W, Awad T, Zayed N. & Esmat G.. Hematological Side effects of Anti-viral Therapy in Egyptian Patients with Chronic Hepatitis C Virus. Am. J. Pharm Tech Res. 4(1): 2249-3387, 2014.
[29]
Stellacci E, Test U, Petrucci E &al. Interferon inhibits maturation of demarcation membranes in megakaryocytes. Biochem J; 377 (8): 367-378, 2010.
[30]
Mihai O, Cristina O & Dan O. Thrombocytopenia in Chronic Hepatitis C. J Gastro intestine Liver Dis.; 19 (4), 381-385, 2010.
[31]
Peck-Radosavljevic M, Wichlas M &Pidlich J. Blunted thrombocytopenia response to interferon alpha induced thrombocytopenia during treatment for hepatitis C. Hepatology; 28(5):142-149, 2007.
[32]
Renou C, Rosenthal E & Cohen P. Incidence of thrompocytopenia in patients with hepatitis C virus infection receiving interferon therapy. A prospective multicenter study of 321 patients. Hepatology; 79 (13): 32-42, 2005.
[33]
Dourakis SP, Deutsch M & hadziyannis SJ. Thrombocytopenia and interferon therapy. J. Hepatol; 25(4): 972- 975, 2006.
[34]
Manns M, Mc Hutchison JG, Gordon SC, Rustgi VK, Shiffman ML. & Reindollar, R. Peg interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet; 358: 958-965, 2001.
[35]
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G & Gonçales FL. Peg interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:975-82, 2002.
[36]
Nemr N, Kishk R & Mandour M. Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C. Indian J Gastroenterol; (1):7-13, 2016.
[37]
Nese N, Gupta R, Bui MH & Amin MB. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Canc Netw; 7 (1): 48-57, 2009.
[38]
Antonini MG, Babudieri S & Maida I. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alpha plus ribavirin. Infection. 36 (4): 250-255, 2008.
[39]
Navas S, Martin J. & Quirogaa JA. Recombinant human granulocyte colony stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients. Cytokine. 8 (7): 313-317, 2010.
[40]
Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K & Hoofnagle JH. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med; 123: 897–903, 1995.
[41]
Camps J., García N., Riezu-Boj JI., Civeira MP & Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol; 19:408–412, 1993.
[42]
Allison MED, Wreghitt T, Palmer CR& Alexander GJM. (1994). Evidence of a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21:1135–1139, 1994.
[43]
Radhakrishnan S, Upadhyay Nihar A, Mohan N, Dhar A, Walia HK. & Zubaid G. Late Development of Diabetes mellitus after Interferon-Alfa and Ribavirin Therapy for Chronic Hepatitis C: A case report. Med PrincPract; 14(4):281-3, 2005.
[44]
Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, O'Rahilly S, Shore S, Tom BD, Alexander GJ. Further evidence for an association between non-insulin dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology; 30 (4):1059-63, 1999.
[45]
Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E & Biasin MR. Insulin-dependent diabetes mellitus during alfa-interferon therapy for chronic viral hepatitis. J Hepatol; 28: 514–517, 1998.
[46]
Tosone G, Borgia IG, Gentile R, Cerini MC, Conte D, Orlando R & Piazza, M. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetologica; 44 (3): 167–169, 2007.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186